Allworth Financial LP lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,117.4% during ...

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

This report, from the Centre for Research in Social Policy (CRSP), is the 12th in a series monitoring the number of people ...

The consensus price target for CRISPR Therapeutics AG (NASDAQ:CRSP) has been adjusted from $72.75 to $65, reflecting changes in financial performance and industry developments. Despite a quarterly ...

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...

Highlights,CRISPR Therapeutics has seen price adjustments from financial firms, reflecting shifts in market expectations.,The ...

The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

Citi analyst Yigal Nochomovitz maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...